Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
AbbVie (ABBV) to acquire Cerevel (CERE) for $8.7 billion; deal 'makes sense' says analyst
December 6, 2023 5:30 PM EST(Updated - December 7, 2023 5:18 AM EST)
AbbVie Inc. (NYSE: ABBV) announced it will acquire Cerevel Therapeutics (NASDAQ: CERE) in a deal that will the former acquire the latter's robust neuroscience pipeline of multiple clinical-stage and preclinical candidates.
The acquisition enhances AbbVie's neuroscience lineup by introducing a diverse array of potentially superior assets. Assets with the potential to revolutionize treatment standards for psychiatric... More
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $45 Per Share, $8.7 Billion Deal
December 6, 2023 4:31 PM ESTAbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across... More
Cerevel Therapeutics (CERE) Halted, News Pending
December 6, 2023 4:29 PM ESTCerevel Therapeutics (NASDAQ: CERE) Halted, News Pending
